高级检索
当前位置: 首页 > 详情页

Assessing the diagnostic accuracy of unilateral systematic biopsy combined with targeted biopsy

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]West China School of Medicine, Sichuan University, Chengdu, Sichuan, China. [4]Department of Nursing, Xiufeng Community Health Service Center, Guilin, Guangxi, China.
出处:
ISSN:

关键词: prostate cancer prostate biopsy multiparametric magnetic resonance imaging utilization unilateral index lesion regional biopsy

摘要:
To evaluate unilateral systematic biopsy (SB) combined with targeted biopsy (TB) and assess its diagnostic accuracy in a real-world, single-centre setting.Patients with ≥1 MRI lesion who underwent both transperineal 12-core and 3-core TB were enrolled in this study. Detection rates for total prostate cancer (PCa) and clinically significant PCa (csPCa) were compared between TB, unilateral SB+TB, and SB+TB. Pathological consistency was assessed using the kappa test, and logistic regression was used to identify potential predictors.A total of 250 men were enrolled, of which 126 (50.4%) and 103 (41.2%) exhibited total PCa and csPCa, respectively. Compared to SB+TB, ipsilateral SB combined with TB (ips-SB+TB) had a comparable csPCa detection rate (99/250 vs 103/250, p=0.125), while fewer clinically insignificant PCa were detected (17/250 vs 23/250, p=0.031). In addition, ips-SB+TB demonstrated superior sensitivity for csPCa (96.1%) with an AUC of 0.98. The ips-SB+TB had a significantly higher positive core rate than SB+TB (472/2244 vs. 563/3744, p<0.001). Moreover, ips-SB+TB also had a high consistency of Gleason grade compared to SB+TB (Kappa=0.89). In the multi-lesion cohort, ips-SB+TB also had a comparable csPCa detection rate compared to SB+TB (63/128 vs. 67/128, p=0.125).In conclusion, our study showed that ips-SB+TB was comparable to SB+TB in detecting csPCa. The results of this study provide valuable insight into the potential of ips-SB+TB as an alternative to SB+TB.Copyright © 2025 Wu, He, Tu, Chen, Jiang, Wang, Chen, Liu, Huang, Tang, Yao and Wei.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
第一作者:
第一作者机构: [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real-world insights from a high-volume center in southwest China [2]Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer. [3]Diagnostic Role of Magnetic Resonance Imaging-Targeted Biopsy for Prostate Cancer in Biopsy-Naïve Men: A Meta-Analysis. [4]Liquid biopsy for promoter methylation in prostate cancer: a promising non-invasive diagnostic weapon [5]The value of transperineal apical prostate biopsy in predicting urethral/apical margin status after radical prostatectomy. [6]Significance of MRI/Transrectal Ultrasound Fusion Three-Dimensional Model-Guided, Targeted Biopsy Based on Transrectal Ultrasound-Guided Systematic Biopsy in Prostate Cancer Detection: A Systematic Review and Meta-Analysis. [7]Clinical and oncologic findings of extraprostatic extension on needle biopsy in de novo metastatic prostate cancer. [8]Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer? [9]The Impact of Prostate Volume on Prostate Cancer Detection: Comparing Magnetic Resonance Imaging with Transrectal Ultrasound in Biopsy-na&#xef;ve Men [10]Artificial intelligence-aided detection for prostate cancer with multi-modal routine health check-up data: an Asian multi-center study

资源点击量:65768 今日访问量:2 总访问量:5150 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号